Abstract
Hypoxia is defined as the inadequate supply of oxygen to the tissue that can occur due to a multitude of causes and is called by various names such as hypoxemic, anemic, ischemic, diffusional, and cytotoxic hypoxia. Cancer-induced hypoxia is an interplay of ischemic, diffusional, and anemic hypoxia, and plays an important role as a prognosticator of the disease and also as a target for treatment modalities. The major mediator of hypoxia in tumor cells is hypoxia-inducible factor (HIF), which is a heterodimeric protein that is upregulated in hypoxic conditions. The consequences of HIF action are the activation and upregulation of several enzymes, transporters, and factors that modulate the neoplastic cell’s metabolic functions that result in functional responses to the hypoxic stressor, which resists apoptosis/necrosis, in addition to modifying and refashioning the local microenvironment to suit the neoplastic cell’s survival. Metastasis—one of the most feared outcomes of neoplasm—has almost all of its steps upregulated or controlled by hypoxia and HIF. Hypoxia is also responsible for drug resistance to various chemotherapeutic agents by different mechanisms. This makes it harder to treat neoplasms that are susceptible to these drugs. Therefore, treatment modalities acting by blocking HIF, in addition to the standard chemotherapeutics, target the neoplasm from all aspects, making it more comprehensive and more effective.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Belisario DC, Kopecka J, Pasino M, Akman M, De Smaele E, Donadelli M, Riganti C (2020) Hypoxia dictates metabolic rewiring of tumors: implications for chemoresistance. Cells 9(12):2598. https://doi.org/10.3390/cells9122598
Bertozzi D, Marinello J, Manzo SG, Fornari F, Gramantieri L, Capranico G (2014) The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther 13(1):239–248. https://doi.org/10.1158/1535-7163.MCT-13-0729. Epub 2013 Nov 19
Brahimi-Horn MC, Chiche J, Pouysségur J (2007) Hypoxia and cancer. J Mol Med (Berl) 85(12):1301–1307. https://doi.org/10.1007/s00109-007-0281-3. Epub 2007 Nov 20
Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26(2):333–339. https://doi.org/10.1007/s10555-007-9063-1
Díaz-Bulnes P, Saiz ML, López-Larrea C, Rodríguez RM (2020) Crosstalk between hypoxia and ER stress response: a key regulator of macrophage polarization. Front Immunol 10:2951. https://doi.org/10.3389/fimmu.2019.02951
DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ (2014) Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol 32(5):458–464. https://doi.org/10.1200/JCO.2013.51.4265. Epub 2014 Jan 6.
Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, Nedaeinia R, Haghjooy Javanmard S, Taherian M, Ahmadlou M, Salehi R, Sadeghi B, Manian M (2021) The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int 21(1):62. https://doi.org/10.1186/s12935-020-01719-5
Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93(4):266–276. https://doi.org/10.1093/jnci/93.4.266
Huang D, Li C, Zhang H (2014) Hypoxia and cancer cell metabolism. Acta Biochim Biophys Sin Shanghai 46(3):214–219. https://doi.org/10.1093/abbs/gmt148. Epub 2014 Jan 3
Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y (2019) Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer 18(1):157. https://doi.org/10.1186/s12943-019-1089-9
Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93(11):1074–1081. https://doi.org/10.1161/01.RES.0000102937.50486.1B. Epub 2003 Oct 23
Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3(3):177–185. https://doi.org/10.1016/j.cmet.2006.02.002
Lu X, Kang Y (2010) Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16(24):5928–5935. https://doi.org/10.1158/1078-0432.CCR-10-1360. Epub 2010 Oct 20
McKeown SR (2014) Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol 87(1035):20130676. https://doi.org/10.1259/bjr.20130676
Mennerich D, Kubaichuk K, Kietzmann T (2019) DUBs, hypoxia, and cancer. Trends Cancer 5(10):632–653. https://doi.org/10.1016/j.trecan.2019.08.005. Epub 2019 Oct 11
Muz B, de la Puente P, Azab F, Azab AK (2015) The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) 11(3):83–92. https://doi.org/10.2147/HP.S93413
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. PubChem Compound Summary for CID 135413511, Tirapazamine; [cited 2022 May 20]. https://pubchem.ncbi.nlm.nih.gov/compound/Tirapazamine
Sebestyén A, Kopper L, Dankó T, Tímár J (2021) Hypoxia signaling in cancer: from basics to clinical practice. Pathol Oncol Res 3(27):1609802. https://doi.org/10.3389/pore.2021.1609802
Simiantonaki N, Taxeidis M, Jayasinghe C, Kurzik-Dumke U, Kirkpatrick CJ (2008) Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer 8:320. https://doi.org/10.1186/1471-2407-8-320
Taylor CT, Colgan SP (2017) Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol 17(12):774–785. https://doi.org/10.1038/nri.2017.103. Epub 2017 Oct 3
Vetsika EK, Koukos A, Kotsakis A (2019) Myeloid-derived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer. Cell 8(12):1647. https://doi.org/10.3390/cells8121647
Acknowledgments
None.
Consent for Publication
No.
Conflict of Interest
The authors declare no conflict of interest.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kulkarni, A., Masarkar, N., Ray, S.K., Mukherjee, S. (2023). Hypoxia’s Function in Cancer. In: Mukherjee, S., Kanwar, J.R. (eds) Hypoxia in Cancer: Significance and Impact on Cancer Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-99-0313-9_2
Download citation
DOI: https://doi.org/10.1007/978-981-99-0313-9_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-0312-2
Online ISBN: 978-981-99-0313-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)